| Literature DB >> 34962573 |
Laura van Iersel1, Renee L Mulder2, Christian Denzer3, Laurie E Cohen4,5,6, Helen A Spoudeas7,8,9, Lillian R Meacham10,11, Elaine Sugden12, Antoinette Y N Schouten-van Meeteren2, Eelco W Hoving2, Roger J Packer13, Gregory T Armstrong14, Sogol Mostoufi-Moab15, Aline M Stades16, Dannis van Vuurden2, Geert O Janssens2,17, Cécile Thomas-Teinturier18,19, Robert D Murray20,21, Natascia Di Iorgi22, Sebastian J C M M Neggers23, Joel Thompson24, Andrew A Toogood25, Helena Gleeson25, Cecilia Follin26, Edit Bardi27,28, Lilibeth Torno29, Briana Patterson10,11, Vera Morsellino30, Grit Sommer31,32, Sarah C Clement33, Deokumar Srivastava34, Cecilie E Kiserud35, Alberto Fernandez36, Katrin Scheinemann37,38,39, Sripriya Raman40, Kevin C J Yuen41, W Hamish Wallace42, Louis S Constine43, Roderick Skinner44, Melissa M Hudson45, Leontien C M Kremer2,46, Wassim Chemaitilly47, Hanneke M van Santen1.
Abstract
Endocrine disorders in survivors of childhood, adolescent, and young adult (CAYA) cancers are associated with substantial adverse physical and psychosocial effects. To improve appropriate and timely endocrine screening and referral to a specialist, the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) aims to develop evidence and expert consensus-based guidelines for healthcare providers that harmonize recommendations for surveillance of endocrine disorders in CAYA cancer survivors. Existing IGHG surveillance recommendations for premature ovarian insufficiency, gonadotoxicity in males, fertility preservation, and thyroid cancer are summarized. For hypothalamic-pituitary (HP) dysfunction, new surveillance recommendations were formulated by a guideline panel consisting of 42 interdisciplinary international experts. A systematic literature search was performed in MEDLINE (through PubMed) for clinically relevant questions concerning HP dysfunction. Literature was screened for eligibility. Recommendations were formulated by drawing conclusions from quality assessment of all evidence, considering the potential benefits of early detection and appropriate management. Healthcare providers should be aware that CAYA cancer survivors have an increased risk for endocrine disorders, including HP dysfunction. Regular surveillance with clinical history, anthropomorphic measures, physical examination, and laboratory measurements is recommended in at-risk survivors. When endocrine disorders are suspected, healthcare providers should proceed with timely referrals to specialized services. These international evidence-based recommendations for surveillance of endocrine disorders in CAYA cancer survivors inform healthcare providers and highlight the need for long-term endocrine follow-up care in subgroups of survivors and elucidate opportunities for further research.Entities:
Keywords: childhood cancer survivor; clinical practice guidelines; endocrine complications; endocrine late effects; radiotherapy late effects
Mesh:
Year: 2022 PMID: 34962573 DOI: 10.1210/endrev/bnab040
Source DB: PubMed Journal: Endocr Rev ISSN: 0163-769X Impact factor: 25.261